Business
Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&A
Oakville, Ontario--(Newsfile Corp. - March 28, 2019) - Cardiol Therapeutics Inc. (TSX : CRDL )...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&AOakville, Ontario--(Newsfile Corp. - March 28, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (\"Cardiol\" or the \"Company\"), a leader in the research and development of pharmaceutical cannabidiol and targeted therapies for inflammatory disease, today announced the filing of its audited year-end financial statements and management's discussion and analysis for the year ended December 31, 2018. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.cardiolrx.com.\"Cardiol Therapeutics achieved a number of important milestones during 2018 which have positioned the Company to commercialize our proprietary, ultra-pure CardiolRx pharmaceutical cannabidiol (CBD) later this year,\" stated David Elsley, President and CEO. \"We are planning to launch our unique CBD formulation in the billion-dollar, supply constrained, Canadian medicinal cannabinoids market where we see a significant opportunity to introduce a premium pharmaceutical brand. We believe that CardiolRx will represent the purest, safest, and most consistent cannabidiol product in a growing market predominantly supplied by low purity products that do not meet the quality standards physicians, pharmacists and consumers expect from medicine. We are also advancing the development of novel therapeutics targeting inflammatory diseases of the heart which are characterized by high mortality, morbidity, and extraordinary healthcare costs.\" Highlights during the 2018 Fiscal Period:We made significant progress with our CardiolRx pharmaceutical CBD program in preparation for product launch in the billion-dollar Canadian market for medicinal cannabinoids. Key accomplishments included:Initializing manufacturing scale-up of our proprietary CardiolRx formulation at Dalton Pharma Services, our global exclusive Health Canada approved, FDA certified, cGMP manufacturer of pharmaceutical cannabinoids. Entering into an exclusive supply agreement for Canada and Mexico with US-based Noramco, Inc., a global leader in the manufacture and supply of pharmaceutical cannabinoids. The Noramco agreement provides Cardiol with access to large-scale metric ton (one million grams) production capacity for ultra-pure pharmaceutical cannabidiol that is unparalleled in the industry....